Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13550-13563

  Zhang, Pei ^a   Guo, Xiaosun ^a   Li, Juan ^a   Yu, Shuwen ^a   Wang, Linlin ^a   Jiang, Guosheng ^b   Yang, Dong ^a   Wei, Zhaolong ^a   Zhang, Nan ^a   Liu, Jie ^a   Sun, Yuping ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

ERK1 2; ILT4; NSCLC; Tumor progression; VEGF C

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN LIKE TRANSCRIPT 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; VASCULOTROPIN C; IMMUNOGLOBULIN RECEPTOR; LILRB2 PROTEIN, HUMAN; MEMBRANE PROTEIN; VEGFC PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; VERY ELDERLY; ANIMAL; BAGG ALBINO MOUSE; DISEASE COURSE; ENZYMOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84931088781     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3624     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Siegel R, Ma J, Zou Z, Jemal A, Cancer statistics, 2014 CA: a cancer journal for clinicians. 2014; 64:9-29.
3. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. International journal of cancer Journal international du cancer. 2005; 117:294-299.
4. Reck M, Heigener DF, Mok T, Soria J-C, Rabe KF. Management of non-small-cell lung cancer: recent developments. The Lancet. 2013; 382:709-719.
5. Vineis P, Wild CP. Global cancer patterns: causes and prevention. The Lancet. 2014; 383:549-557.
6. Chui CS, Li D. Role of immunolglobulin-like transcript family receptors and their ligands in suppressor T-cellinduced dendritic cell tolerization. Human immunology. 2009; 70:686-691.
7. Colonna M, Nakajima H, Cella M. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Seminars in Immunology. 2000; 12:121-127.
8. Marco Colonna HN, Marina Cella. Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. Journal of Leukocyte Biology. 1999; 66.
9. Ravetch JV. Immune Inhibitory Receptors. Science. 2000; 290:84-89.
10. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997; 186:1809-1818.
11. Nikolova M, Musette P, Bagot M, Boumsell L, Bensussan A. Engagement of ILT2/CD85j in Sezary syndrome cells inhibits their CD3/TCR signaling. Blood. 2002; 100:1019-1025.
12. Colovai AI, Tsao L, Wang S, Lin H, Wang C, Seki T, Fisher JG, Menes M, Bhagat G, Alobeid B, Suciu-Foca N. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytometry Part B, Clinical cytometry. 2007; 72:354-362.
13. Mirjana Urosevic JK, Günter Burg, Reinhard Dummer. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Blood. 2004; :1796-1798.
14. Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C, Huynh H, Kang X, Silvany R, Wan X, Ye J, Canto AP, Chen SH, Wang HY, Ward ES, Zhang CC. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature. 2012; 485:656-660.
15. Khan MF, Bahr JM, Yellapa A, Bitterman P, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Barua A. Expression of Leukocyte Inhibitory Immunoglobulinlike Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer. Translational Oncology. 2012; 5:85-91.
16. Zhang Y, Lu N, Xue Y, Zhang M, Li Y, Si Y, Bian X, Jia Y, Wang Y. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance. Molecular medicine reports. 2012; 5:910-916.
17. Liu J, Wang L, Gao W, Li L, Cui X, Yang H, Lin W, Dang Q, Zhang N, Sun Y. Inhibitory receptor immunoglobulin- like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10. Diagnostic pathology. 2014; 9:85.
18. Sun Y, Liu J, Gao P, Wang Y, Liu C. Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. Chest. 2008; 134:783-788.
19. Carbone C, Piro G, Fassan M, Tamburrino A, Mina MM, Zanotto M, Chiao PJ, Bassi C, Scarpa A, Tortora G, Melisi D. An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget. 2014.
20. Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, Xie W, Chen Z, Zhu B. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer science. 2010; 101:2384-2390.
21. Zhu C, Qi X, Chen Y, Sun B, Dai Y, Gu Y. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1- induced VEGF-C upregulation in breast cancer. Journal of cancer research and clinical oncology. 2011; 137:1587-1594.
22. Khromova N, Kopnin P, Rybko V, Kopnin BP. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene. 2012; 31:1389-1397.
23. Joël LeMaoult KZ, Caroline Le Danff, Edgardo D. Carosella. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. The FASEB Journal. 2005; 10:23.
24. Castellaneta A, Mazariegos GV, Nayyar N, Zeevi A, Thomson AW. HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation. 2011; 91:1132-1140.
25. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:8357-8362.
26. Ristich V, Zhang W, Liang S, Horuzsko A. Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells. Human immunology. 2007; 68:264-271.
27. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell death and differentiation. 2009; 16:368-377.
28. McCubrey JA, Steelman LS, Chappell WH, Abrams S L, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et biophysica acta. 2007; 1773:1263-1284.
29. Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacology & therapeutics. 2014; 141:160-171.
30. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth factors. 2006; 24:21-44.
31. Adjei AA. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Clinical lung cancer. 2005; 7:221-223.
32. Maraver A, Fernandez-Marcos PJ, Herranz D, Canamero M, Munoz-Martin M, Gomez-Lopez G, Mulero F, Megias D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A, Serrano M. Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer cell. 2012; 22:222-234.
33. Chen Y, Jiang L, She F, Tang N, Wang X, Li X, Han S, Zhu J. Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Molecular and cellular biochemistry. 2010; 345:77-89.
34. Su JL, Chen PS, Chien MH, Chen PB, Chen YH, Lai CC, Hung MC, Kuo ML. Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer cell. 2008; 13:557-560.
35. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, Hung MC, Kuo ML. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer cell. 2006; 9:209-223.
36. Timoshenko AV, Rastogi S, Lala PK. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. British journal of cancer. 2007; 97:1090-1098.
37. Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, Lim S, Nakamura M, Andersson P, Wang J, Sun Y, Dissing S, He X, Yang X, Cao Y. TNFR1 mediates TNF-alphainduced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun. 2014; 5:4944.
38. Shinriki S, Jono H, Ueda M, Ota K, Ota T, Sueyoshi T, Oike Y, Ibusuki M, Hiraki A, Nakayama H, Shinohara M, Ando Y. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. The Journal of pathology. 2011; 225:142-150.
39. Angela Coxon, Beth Ziegler, Stephen Kaufman, Man Xu, Hongyu Wang, Dawn Weishuhn, Joanna Schmidt, Heather Sweet, Charlie Starnes, Saffran D, Polverino A. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small cell lung cancer xenograft models. Molecular cancer. 2012; 11:70.
40. Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, Sone S. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res. 2006; 16:15-26.
41. Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, Frasca D, Koker M, Konig K, Meder L, Rauh D, Buettner R, Wolf J, Brekken RA, Neumaier B, Christofori G, et al. Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013; 123:1732-1740.
42. Takahashi O, Komaki R, Smith PD, Jurgensmeier JM, Rya A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:1641-1654.